Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone
Frontiers in Pharmacology · 12.08.2024 · 15
DOI: 10.3389/fphar.2024.1396790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.08.2024. Verfasst von Dandan Jin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Phase I Clinical Trials Unit, Nanjing Drum Tower Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The anti-nerve growth factor antibody class of drugs interrupts signaling by blocking NGF binding to TrkA receptors for the treatment of pain; however, this target class of drugs has been associated with serious adverse effects in the joints during clinical trials. DS002 is a novel anti-nerve growth factor antibody drug independently developed by Guangdong Dashi Pharmaceuticals. The main purpose of this study is to explore the correlation between DS002 and pain as well as cartilage and bone metabolism with the help of metabolomics technology and the principle of enzyme-linked reaction, and to examine whether DS002 will produce serious adverse effects in joints caused by its same target class of drugs, in order to provide more scientific basis for the safety and efficacy of DS002. Our results showed that DS002 mainly affected the metabolism of aromatic amino acids and other metabolites, of which six metabolites, l -phenylalanine, 5-hydroxytryptophan, 5-hydroxytryptamine hydrochloride, 3-indolepropionic acid, kynuric acid, and kynurenine, were significantly altered, which may be related to the effectiveness of DS002 in treating pain. In addition, there were no significant changes in biological indicators related to cartilage and bone metabolism in vivo , suggesting that DS002 would not have a significant effect on cartilage and bone metabolism, so we hypothesize that DS002 may not produce the serious adverse effects in joints caused by its fellow target analogs. Therefore, the Anti-NGF analgesic drug DS002 has the potential to become a promising drug in the field of analgesia, providing pain patients with an efficient treatment option without adverse effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Phase I Clinical Trials Unit, Nanjing Drum Tower Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Phase I Clinical Trials Unit, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Phase I Clinical Trials Unit, China Pharmaceutical University Nanjing Drum Tower Hospital, Nanjing, China.
- Dartsbio Pharmaceuticals Ltd., Zhongshan, Guangdong, China.
Zitieren
APA
Jin, D., Yang, H., Chen, Z., Hong, Y., Ma, H., Xu, Z., Cao, B., Fei, F., Zhang, Y., Wu, W., Tang, L., Sun, R., Wang, C., & Li, J. (2024). Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1396790
Vancouver
Jin D, Yang H, Chen Z, Hong Y, Ma H, Xu Z, et al. Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1396790
BibTeX
@article{Jin2024,
author = {Jin, Dandan and Yang, Haoyi and Chen, Zhiyou and Hong, Yuxin and Ma, Hehua and Xu, Zhenzhen and Cao, Bei and Fei, Fei and Zhang, Yuwen and Wu, Weitao and Tang, Lei and Sun, Runbin and Wang, Chunhe and Li, Juan},
title = {Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1396790}
}
EUVIMED